GLP-1RA Use Safe for Cancer Patients, Study Finds

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for people with type 2 diabetes and congestive heart failure. However, concerns have been raised about their potential to cause acute kidney injury (AKI), especially in patients undergoing cancer treatment. New research, to be presented at ASN Kidney Week 2024, suggests that these concerns may be unfounded.

Study Finds No Increased AKI Risk

A recent study analyzed medical records of 14,783 patients receiving anti-cancer medications, including cytotoxic and targeted immunotherapies, over a one-year period. Approximately 9% of these patients were also treated with GLP-1RAs.

The results showed that AKI occurred in 7.2% of those taking GLP-1RAs and 6.4% of those who were not. This suggests that GLP-1RA use does not increase the risk of AKI in patients undergoing cancer therapy.

Continuing Benefits Despite Concerns

Dr. Swetha Rani Kanduri, MD, the corresponding author of the study from Ochsner Health, stated, “Given the cardiovascular and anti-diabetic benefits of GLP-1RAs, we suggest that these agents can be safely continued during administration of anti-cancer therapy. We invite prospective studies to further elaborate on the effects of GLP-1RAs in patients with cancer.”

Given the cardiovascular and anti-diabetic benefits of GLP-IRA, we suggest that these agents can be safely continued during administration of anti-cancer therapy. We invite prospective studies to further elaborate on the effects of GLP1-RA in patients with cancer.”

Swetha Rani Kanduri, MD,
corresponding author of Ochsner Health

Further Research Encouraged

While this study provides reassuring news for patients and healthcare providers, further research is needed to fully understand the long-term effects of GLP-1RA use in conjunction with cancer therapies.

Learn more about GLP-1RAs and their potential benefits by talking to your doctor.